STERIS (NYSE:STE) Releases FY 2025 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 9.050-9.250 for the period, compared to the consensus estimate of 9.330. The company issued revenue guidance of $5.5 billion-$5.5 billion, compared to the consensus revenue estimate of $5.7 billion. STERIS also updated its FY25 guidance to $9.05 to $9.25 EPS.

STERIS Stock Down 1.3 %

NYSE:STE traded down $2.78 on Wednesday, reaching $210.09. The stock had a trading volume of 938,097 shares, compared to its average volume of 469,991. STERIS has a 12-month low of $185.22 and a 12-month high of $254.00. The stock has a market cap of $20.76 billion, a P/E ratio of 37.28 and a beta of 0.81. The company has a current ratio of 2.43, a quick ratio of 1.49 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average of $217.58 and a 200 day moving average of $216.01.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.15. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.41 billion. STERIS had a return on equity of 13.67% and a net margin of 10.48%. STERIS’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.30 EPS. On average, research analysts predict that STERIS will post 8.67 earnings per share for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 26th. Stockholders of record on Wednesday, June 12th will be given a dividend of $0.52 per share. The ex-dividend date is Wednesday, June 12th. This represents a $2.08 annualized dividend and a dividend yield of 0.99%. STERIS’s payout ratio is 36.43%.

Analyst Ratings Changes

Several analysts have issued reports on STE shares. Stephens reaffirmed an overweight rating and set a $250.00 target price on shares of STERIS in a report on Friday, February 9th. TheStreet raised shares of STERIS from a c+ rating to a b rating in a report on Wednesday, February 7th. Needham & Company LLC reissued a hold rating on shares of STERIS in a report on Friday, April 12th. KeyCorp started coverage on shares of STERIS in a report on Tuesday, February 6th. They issued an overweight rating and a $253.00 price target for the company. Finally, StockNews.com lowered shares of STERIS from a buy rating to a hold rating in a research note on Friday, May 3rd. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $239.60.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.